These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 6093515)

  • 21. The antimicrobial activity of cefpirome, a new cephalosporin.
    Wise R; Andrews JM; Cross C; Piddock LJ
    J Antimicrob Chemother; 1985 Apr; 15(4):449-56. PubMed ID: 3874198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activity of ertapenem: review of recent studies.
    Wexler HM
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [In vitro effect of ceftriaxone on hospital bacteria. Line of regression and critical values].
    Cluzel M; Chanal M; Sirot D; Sirot J; Cluzel R
    Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):473-6. PubMed ID: 3937122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular correlation between in vitro and in vivo activity of beta-lactam and beta-lactamase inhibitor combinations against methicillin-resistant Staphylococcus aureus.
    Fasola EL; Fasching CE; Peterson LR
    J Lab Clin Med; 1995 Feb; 125(2):200-11. PubMed ID: 7844469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cefodizime, an aminothiazolylcephalosporin. I. In vitro activity.
    Limbert M; Klesel N; Seeger K; Seibert G; Winkler I; Schrinner E
    J Antibiot (Tokyo); 1984 Aug; 37(8):892-900. PubMed ID: 6090373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of cefodizime.
    Knothe H; Shah PM
    Infection; 1992; 20 Suppl 1():S3-8. PubMed ID: 1526673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [In vitro bacteriostatic activity of cefmenoxime (SCE 1365), cefotaxime and moxalactam].
    Husson MO; Bryskier A; Izard D; Leclerc H
    Pathol Biol (Paris); 1983 May; 31(5):347-50. PubMed ID: 6312395
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Carbapenem antibiotics].
    Watanabe A
    Nihon Rinsho; 2003 Feb; 61 Suppl 2():737-43. PubMed ID: 12722309
    [No Abstract]   [Full Text] [Related]  

  • 29. Excellent activity of FK037, a novel parenteral broad-spectrum cephalosporin, against methicillin-resistant staphylococci.
    Mine Y; Watanabe Y; Sakamoto H; Hatano K; Kuno K; Kamimura T; Tawara S; Matsumoto Y; Matsumoto F; Kuwahara S
    J Antibiot (Tokyo); 1993 Jan; 46(1):99-119. PubMed ID: 8436564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [In vitro activity of ceftizoxime on hospital bacteria. Results of a multicenter study].
    Soussy CJ; Deforges L; Le Van Thoi J; Thabaut A; Meyran M; Chanal M; Cluzel M; Brun Y; Coulet M; Fleurette J
    Pathol Biol (Paris); 1984 May; 32(5):326-30. PubMed ID: 6330645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Why are carbapenems active against Enterobacter cloacae resistant to third generation cephalosporins?
    Pechère JC
    Scand J Infect Dis Suppl; 1991; 78():17-21. PubMed ID: 1658922
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro activity of CP-65,207, a new penem antimicrobial agent, in comparison with those of other agents.
    Gootz T; Retsema J; Girard A; Hamanaka E; Anderson M; Sokolowski S
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1160-6. PubMed ID: 2679370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anaerobic bacteria and beta-lactam antibiotics.
    Nord CE; Olsson-Liljequist B
    Scand J Infect Dis Suppl; 1984; 42():72-82. PubMed ID: 6335601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Third-generation cephalosporins: a critical evaluation.
    Barriere SL; Flaherty JF
    Clin Pharm; 1984; 3(4):351-73. PubMed ID: 6432420
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activity of CGP 31523A, a broad-spectrum cephalosporin, in comparison with those of other agents.
    Wise R; Cross C; Andrews JM
    Antimicrob Agents Chemother; 1984 Dec; 26(6):876-80. PubMed ID: 6524904
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MEN 10700, a new penem antibiotic: in-vitro activity and its correlation with beta-lactamase stability, PBP affinity and diffusion through the bacterial cell wall.
    Fontana R; Altamura M; Arcamone F; Mazzariol A; Morandotti G; Sperning R; Cornaglia G
    J Antimicrob Chemother; 1998 May; 41(5):513-25. PubMed ID: 9630405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ceftriaxone against gram-negative and gram-positive bacteria: bactericidal and post-antibiotic effect.
    Ravizzola G; Bonfanti C; Savoldi E; Turano A
    Chemioterapia; 1985 Jun; 4(3):204-8. PubMed ID: 3875430
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro antibacterial activity of FK041, a new orally active cephalosporin.
    Watanabe Y; Hatano K; Matsumoto Y; Tawara S; Yamamoto H; Kawabata K; Takasugi H; Matsumoto F; Kuwahara S
    J Antibiot (Tokyo); 1999 Jul; 52(7):649-59. PubMed ID: 10513845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overview of preclinical studies with ciprofloxacin.
    Sanders CC; Sanders WE; Goering RV
    Am J Med; 1987 Apr; 82(4A):2-11. PubMed ID: 3646829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro evaluation of E1040, a new cephalosporin with potent antipseudomonal activity.
    Watanabe N; Katsu K; Moriyama M; Kitoh K
    Antimicrob Agents Chemother; 1988 May; 32(5):693-701. PubMed ID: 3134847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.